Foundayo Pill Daily Weight Loss Treatment

In Stock

Price range: £99.00 through £179.00

Foundayo is a once-daily oral tablet form of orforglipron, a non-peptide GLP-1 receptor
agonist licensed for weight management. Approved by the MHRA on 10 August 2026, it made the UK the first country in Europe to
license the medication. Developed by Eli Lilly – the company behind Mounjaro.

Start Assessment
Want it delivered by Tomorrow?
Order within 0h 0m 0s

Description

Foundayo Tablets (Orforglipron) — Now MHRA Approved, August 2026

Foundayo is a once-daily oral tablet form of orforglipron, a non-peptide GLP-1 receptor
agonist licensed for weight management alongside a reduced-calorie diet and increased
physical activity, and for improving blood sugar control in adults with type 2 diabetes.
Approved by the MHRA on 10 August 2026, it made the UK the first country in Europe to
license the medication. Developed by Eli Lilly the – company behind Mounjaro. Foundayo
is a small-molecule GLP-1 medicine rather than a modified copy of the natural hormone,
which is part of why it can be manufactured and absorbed as an ordinary tablet, with no
fasting or water rules.

How Does It Work?
Orforglipron mimics the action of GLP-1, a hormone released by the gut after eating, by
binding to and activating the same receptor in the body. It acts on appetite centres in the
brain to reduce hunger and food cravings, increases feelings of fullness, and helps people
eat less as a result. In people with type 2 diabetes, it also helps lower blood sugar when
levels are high. Unlike the Wegovy pill, Foundayo is not a modified peptide protected by an
absorption enhancer, as a small molecule, it can be taken at any time of day, with or
without food or water.

How Effective Is It?
The MHRA approval draws on the Phase 3 ATTAIN clinical trial programme.

  • ATTAIN-1 (adults with obesity/overweight, without diabetes): at 72 weeks,
    participants on the highest dose lost an average of approximately 12.4% of body
    weight, versus approximately 0.9% with placebo. Around 59.6% of participants on the
    highest dose lost at least 10% of their body weight, and 39.6% lost at least 15%.
  • ATTAIN-2 (adults with obesity/overweight and type 2 diabetes): at 72 weeks, the
    highest dose produced an average weight reduction of approximately 9.6%, versus
    approximately 2.5% with placebo, alongside meaningful improvements in blood sugar
    control (HbA1c).

Weight loss with Foundayo has generally been more modest than with the highest doses of
injectable GLP-1 medicines, but it offers a needle-free, once-daily alternative with fewer
administration rules than other oral GLP-1 tablets.

 

Foundayo vs the Wegovy Pill – Key Differences

A simple side-by-side comparison.

Feature Foundayo Wegovy Pill
Active ingredient Orforglipron (small-molecule GLP-1 agonist) Semaglutide (peptide GLP-1 agonist)
Frequency Once daily Once daily
Needle-free ✓ Yes ✓ Yes
Food / water rules None — can be taken any time, with or without food Empty stomach, small amount of plain water, 30-minute wait before eating
Storage Room temperature Room temperature
Also licensed for type 2 diabetes ✓ Yes ✕ No
Available on NHS Not currently (NICE evaluation pending) Not currently

 

Ingredients and Composition

Active Ingredient
Orforglipron — a non-peptide, small-molecule GLP-1 receptor agonist, believed to be
available in a titrating range of strengths (starting around 0.8 mg, with maintenance doses up
to approximately 17.2 mg) as the dose is increased gradually to manage tolerability.

Formulation
Because orforglipron is a small molecule rather than a peptide, it does not require the
absorption-enhancing technology used in some other oral GLP-1 tablets, which is part of
why it can be taken without fasting or water restrictions. Full inactive ingredient information
and confirmed UK strengths will be published when UK prescribing information is finalised at
launch.

Common Side Effects of Foundayo
Side effects are expected to be broadly similar to other GLP-1 medicines, and are largely
gastrointestinal. They tend to be dose-related and often ease as the body adjusts, which is
why the dose is increased gradually.
Common Side Effects

  • Nausea
  • Vomiting
  •  Diarrhoea
  • Constipation
  • Stomach pain, indigestion, bloating, reflux
  • Reduced appetite
  • Headache
  • Fatigue

Serious Side Effects (Rare but Important)

  • Pancreatitis – Severe and persistent stomach pain, with or without vomiting
  • Gallbladder problems – Gallstones, sometimes linked to rapid weight loss
  •  Dehydration – Dizziness, fainting, very dark urine, or not passing urine
  •  Severe allergic reaction- Swelling of the face or throat, wheezing, or severe rash
  • Low blood sugar – Mainly if used alongside insulin or a sulfonylurea in people with diabetes

If you experience any severe side effects, seek immediate medical attention.

Do Not Use If:

  • You are allergic to orforglipron or any ingredients in the product
  • You are pregnant, breastfeeding, or think you may be pregnant
  • You have a personal or family history of certain thyroid cancers, or other conditions
    your prescriber advises against it for

(This list is a general guide, always check the full Patient Information Leaflet and speak to
a prescriber about your individual medical history before starting treatment.)

Help & Information

Frequently Asked Questions

Everything you need to know about Foundayo, how it works and what to expect.


01

What is Foundayo?

+

Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist made by Eli Lilly. It is licensed in the UK for weight management in adults with obesity or overweight with a weight-related health condition, and for improving blood sugar control in adults with type 2 diabetes. It was approved by the MHRA on 10 August 2026, making the UK the first country in Europe to license it.


02

How is Foundayo different from other GLP-1 weight loss medicines, like the Wegovy pill or Mounjaro?

+

Unlike Semaglutide (Wegovy, Ozempic) and Tirazeptide (Mounjaro), which are injectable peptides, orforglipron is a small, non-peptide molecule that activates the same GLP-1 receptor. That is also what sets it apart from the Wegovy pill: because it isn’t a peptide needing protection from stomach acid, Foundayo can be taken at any time of day, with or without food or water; there is no fasting or 30-minute wait involved. It is also licensed for type 2 diabetes, which the Wegovy pill currently isn’t.


03

What strengths is Foundayo available in?

+

Doses are titrated gradually to help with tolerability, starting low and increasing over several weeks to a maintenance dose. Reported strengths from trial and early product information range from around 0.8 mg up to approximately 17.2 mg. Final confirmed UK strengths and dosing schedule will be set out in the official prescribing information at launch.


04

How much weight can I expect to lose?

+

In the ATTAIN-1 trial (people without diabetes), participants on the highest dose lost an average of around 12.4% of their body weight over 72 weeks, compared with about 0.9% on placebo, with roughly 6 in 10 losing at least 10% of their body weight. In the ATTAIN-2 trial (people with type 2 diabetes), the highest dose produced an average weight loss of around 9.6%, versus about 2.5% on placebo. Individual results vary, and weight loss is generally somewhat lower than with the highest doses of injectable GLP-1 medicines.


05

Do I need to take Foundayo on an empty stomach or with water rules?

+

No. This is one of the main practical advantages of Foundayo: it can be taken at any time of day, with or without food or water, unlike the Wegovy pill and some other oral GLP-1 treatments.


06

What are the most common side effects?

+

The most commonly reported side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation, indigestion, bloating and reflux — along with reduced appetite, headache and fatigue. These are usually dose-related and tend to ease as your body adjusts, which is why the dose is increased gradually.


07

Who is Foundayo suitable for?

+

It is licensed for adults with a BMI of 30 or above, or a BMI of 27–30 with at least one weight-related condition such as high blood pressure or type 2 diabetes, for use alongside a reduced-calorie diet and increased physical activity. It is also licensed for adults with type 2 diabetes to help improve blood sugar control. A prescriber will assess your suitability based on your full medical history.

Additional information

Strength

0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg

Pack Size

30 Tablets